A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Advanced CarcinomaNon-small Cell Lung Cancer
Interventions
DRUG

Aflibercept

Administered in combination with the other two interventions via intravenous infusion.

DRUG

Pemetrexed

Administered in combination with the other two interventions via intravenous infusion.

DRUG

Cisplatin

Administered in combination with the other two interventions via intravenous infusion.

Trial Locations (15)

10467

Montefiore Medical Center, The Bronx

14263

Roswell Park Cancer Institute, Buffalo

16505

Erie Regional Cancer Center, Erie

26003

Schiffler Cancer Center - Medical Oncology Division, Wheeling

28204

Presbyterian Hospital Center for Cancer Research, Charlotte

33435

Palm Beach Institute of Hematology and Oncology, Boynton Beach

41701

Kentucky Cancer Clinic, Hazard

60141

Edward Hines Jr. VA Medical Center, Hines

72205

University of Arkansas for Medical Science, Little Rock

85715

Arizona Cancer Institute, LLC, Tucson

87131

UNM Cancer Clinic, Albuquerque

94305

Stanford University Medical Center, Stanford

21231-1000

Sidney Kimmel Comprehensive Cancer Center, Baltimore

03756

Dartmouth-Hitchcock Medical Center, Lebanon

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT00794417 - A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma | Biotech Hunter | Biotech Hunter